Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 15/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1957956 | 0.73 | GRM2 (0.50) | GRM2 | |
| SCHEMBL1956444 | 0.70 | GRM2 (0.38) | GRM2KCNMA1MGAMAMY1AGAA | |
| SCHEMBL10734042 | 0.69 | SLC9A1 (0.48) | GRM2KCNMA1GAATLR8 | |
| SCHEMBL378660 | 0.67 | POLB (0.50) | GRM2KCNMA1GAATLR8 | |
| Water SCHEMBL3673310 | 0.65 | POLB (0.48) | GRM2KCNMA1GAATLR8 | |
| SCHEMBL3767410 | 0.65 | ACHE (0.39) | GRM2KCNMA1MGAMAMY1AGAA | |
| SCHEMBL8146888 | 0.65 | MAPT (0.48) | KCNMA1GAATLR8 | |
| SCHEMBL8425686 | 0.65 | ACHE (0.39) | GRM2KCNMA1GAATLR8 | |
| SCHEMBL8907627 | 0.63 | KCNMA1 (0.45) | KCNMA1MGAMAMY1AGAASI | |
| SCHEMBL4233106 | 0.63 | GRM2 (0.49) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ANTHONY NEVILLE J | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RNGTT, RRM2B, RRM2 | GRM2 4302/4885KCNMA1 3180/4885MGAM 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.